GRO Biosciences

GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency, stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders and autoimmunity. The company, founded by Dr. George Church, is located at the Harvard Life Lab, a shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars.

Boston Business Journal: George Church startup bags $2M in quest to create ‘designer’ drugs

Harvard geneticist and serial biotech entrepreneur George Church has co-founded a new startup that aims to develop “designer proteins” targeting a range of disorders. The company, called GRO Biosciences, was spawned in the Harvard Life Lab and emerged from stealth mode on Thursday with $2.1 million in seed funding.

Read the full story at The Boston Business Journal